Recent clinical trials on TAVR devices proved that these devices are non-inferior, and possibly superior, to
surgical aortic valve replacement (SAVR) within the intermediate risk patient population. These trials were
also noteworthy for the low complication rates observed in the TAVR groups. As TVAR’s application moves
from inoperable and high risk patients to patients who have moderate or lower risk for open heart surgery,
the market will expand exponentially in the coming years.
Make an Enquiry:-
https://www.infiniumglobalresearch.com/Reports/MakeEnquiryRequest/306
Geographic Coverage
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and
Rest of the World. In this section the key trends and market size for each geography is provided over the
period of 2015-2023.
The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific
includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France,
Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North
America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential
for the market growth owing to rapid growth in markets such as India and China. The APAC region is
projected to experience a growth at a CAGR of x.x% over the period of 2017-2023.
Companies Profiled:
The report provides profiles of the companies in the global transcatheter aortic valve replacement market
such as, Edwards Lifesciences Corp., Boston Scientific Corp., Direct Flow medical, Inc., Bracco SpA, JenaValve
Infinium Global Research